Notice of IMC Shareholder Presentation
Source: RNS
SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Group" or the "Company")
Presentation on Superdrug Commercial Agreement
via Investor Meet Company platform
27 June 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, will be providing a short presentation to shareholders on Thursday 3 July 2025 at 11am BST about the recently signed exclusive UK commercial agreement with Superdrug Stores plc, one of the UK's leading beauty and health retailers, related to its AxisBiotix™ food supplements to alleviate the symptoms of inflammatory skin conditions.
The presentation will be open to all existing and potential SkinBioTherapeutics shareholders. Investors who already follow SkinBioTherapeutics on the Investor Meet Company (IMC) platform will be invited automatically. Investors can sign up to Investor Meet Company for free Here.
The Company intends to hold an IMC shareholder presentation at a later date for a pre-close trading update.
-Ends-
For more information please contact:
|
SkinBioTherapeutics plc Stuart J. Ashman, CEO
|
+44 (0) 191 495 7325
|
|
Singer Capital Markets (Nominated Adviser & Broker) Philip Davies Sam Butcher Patrick Weaver
|
+44 (0) 020 7496 3000
|
|
Vigo Consulting (financial press) Rozi Morris
|
+44 (0) 20 7390 0230 SkinBio@vigoconsulting.com
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements that harness the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, a food supplement to alleviate the symptoms of inflammatory skin conditions, is sold directly and via Amazon, and will be sold via an exclusive UK commercial deal with Superdrug Stores plc later in 2025.
The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
